Related Experiment Videos
Bleomycin-induced mutagenesis in repackaged lambda phage: base substitution hotspots at the sequence C-G-C-C
Abstract:
DNA isolated from lambda phage was treated with bleomycin A2 plus Fe2+. The bleomycin-damaged DNA was added to lambda packaging extracts and the resulting phage were grown in SOS-induced E. coli. Under these conditions, treatment of the DNA with 0.8 microM bleomycin reduced the viability of the repackaged phage to 3% and increased the frequency of clear-plaque mutants in the progeny by a factor of 16. Bleomycin-induced mutations which mapped to the DNA-binding domain of the cI gene were subjected to DNA-sequence analysis. The most frequent events were single-base substitutions at G:C base pairs, nearly all of which occurred at cytosines in the sequence Py-G-C. Cytosines in the third position of the sequence C-G-C-C were particularly susceptible to mutation. At A:T base pairs, mutations were less frequent and were a mixture of single-base substitutions and -1 frameshifts, occurring primarily at G-T and A-T sequences. Thus, the overall specificity of bleomycin-induced mutations matches that of bleomycin-induced DNA lesions (strand breaks and apyrimidinic sites), which are formed at G-C (particularly Py-G-C), G-T and, to a lesser extent, A-T sequences. Furthermore, the frequency of various types of substitutions was consistent with selective incorporation of A and T residues opposite apyrimidinic sites at these sequences. The highly selective nature of bleomycin-induced mutations may explain the lack of mutagenesis by this compound in a number of reversion assays.
Insights
Bleomycin A2 damages DNA, causing mutations primarily at specific G:C sequences. This DNA damage specificity explains bleomycin
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- Bleomycin is an anticancer drug known to induce DNA damage.
- Understanding the mutagenic specificity of bleomycin is crucial for its therapeutic application and for studying DNA repair mechanisms.
Purpose of the Study:
- To investigate the specific types and locations of mutations induced by bleomycin A2 in lambda phage DNA.
- To correlate the observed mutations with the known DNA damage profile of bleomycin.
Main Methods:
- Lambda phage DNA was treated with bleomycin A2 and Fe2+.
- Damaged DNA was used to generate phage, which were then propagated in SOS-induced E. coli.
- Mutant phage were isolated, and mutations within the cI gene were analyzed using DNA sequencing.
Main Results:
- Bleomycin treatment significantly reduced phage viability and increased mutation frequency.
- Mutations predominantly occurred as single-base substitutions at G:C base pairs, particularly cytosines in Py-G-C sequences.
- Specific G:C sequences (C-G-C-C) and certain A:T sequences (G-T, A-T) were hotspots for mutation, consistent with bleomycin's DNA lesion profile.
Conclusions:
- Bleomycin A2 induces mutations with a high degree of sequence specificity, mirroring its DNA damaging activity.
- The observed mutation patterns suggest selective nucleotide incorporation opposite DNA lesions.
- This specificity may account for bleomycin's lack of mutagenicity in certain experimental assays.